Effects of Metformin on the Cerebral Metabolic Changes in Type 2 Diabetic Patients
Figure 1
SPM analysis to compare cerebral FDG uptake between MET-group patients (taking metformin), noMET-group patients (not taking metformin), and wdMET-group patients (withdrawing from metformin). (a) MET versus noMET; (b) wdMET versus noMET; and (c) MET versus wdMET. The voxel-wise comparisons included age, body mass index, fasting blood sugar, and education as nuisance variables. Top: SPM glass brain render of the statistical voxel-wise comparisons (black: hypermetabolic regions in the former; light gray: hypometabolic regions in the former). Bottom: SPM results, slice renders of the significant clusters displayed on a T1 template overlaid with magnetic resonance images by SPM5 extension xjView 8.1 (red: hypermetabolic regions in the former; blue: hypometabolic regions in the former). All results are presented at a threshold of , uncorrected, voxels.
